The Rise of Low-Dose Combination Therapies in Cardiovascular Disease Management
The landscape of cardiovascular disease treatment is shifting, with a growing emphasis on early intervention and simplified regimens. Recent presentations at the Korean Society of Cardiovascular Intervention (KSIC) 2026 highlighted the potential of low-dose combination therapies, specifically Hanmi Pharmaceutical’s Amoprel and Rosuzet, to reshape how doctors approach hypertension and hyperlipidemia.
Amoprel: A New Paradigm for Early Hypertension Treatment?
Traditionally, hypertension treatment has often followed a step-wise approach, starting with single-agent therapy and escalating as needed. However, emerging evidence suggests that low-dose combination therapies like Amoprel – a first-in-class 1/3 dose triple combination antihypertensive – may offer a more effective and patient-friendly alternative.
Professor Jonghwa Ahn of Gyeongsang National University Hospital presented data demonstrating Amoprel’s non-inferiority to amlodipine 5mg in reducing systolic blood pressure. Importantly, the research also indicated a reduction in ankle circumference, potentially mitigating the edema often associated with amlodipine employ. This suggests a more favorable side effect profile.
The HM-APOLLO-302 study further supports this shift, showing that Amoprel achieved superior systolic blood pressure reduction compared to rosartan 50mg monotherapy. This is aligning with updated guidelines from organizations like the European Society of Cardiology, the European Society of Hypertension, and the American Heart Association/American College of Cardiology, which increasingly recommend low-dose combination therapies for their efficacy and potential to improve patient adherence.
Rosuzet: Optimizing LDL-C Control with Early Combination Therapy
Similar trends are emerging in the management of hyperlipidemia. Professor Dong-Oh Kang of Korea University Hospital emphasized the growing recognition of the need to lower LDL-C targets, leading to increased interest in ezetimibe-based combination therapies.
Recent observational studies, Uncomplicated-ROSUZET and EROICA, along with new clinical research, have demonstrated the effectiveness of Rosuzet 10/2.5mg in achieving LDL-C levels below 100 mg/dL in a significant percentage of patients (88.1% in a study of over 4,000 patients). The data also showed that switching from statin monotherapy to Rosuzet resulted in further LDL-C reduction across all patient groups.
This supports the idea of proactively addressing LDL-C levels early in treatment, minimizing cumulative LDL-C exposure and potentially reducing cardiovascular risk. The findings suggest that Rosuzet could become a cornerstone of initial therapy for many patients.
The Future of Cardiovascular Care: Personalized, Proactive, and Simplified
The presentations at KSIC 2026 underscore a broader trend towards more personalized and proactive cardiovascular care. The focus is shifting from simply reacting to established disease to preventing its progression through early intervention and optimized treatment strategies.
Low-dose combination therapies like Amoprel and Rosuzet represent a significant step in this direction, offering the potential for improved efficacy, reduced side effects, and enhanced patient adherence. Hanmi Pharmaceutical’s commitment to generating clinical evidence to support these therapies is crucial for driving adoption and improving patient outcomes.
Did you recognize? Hanmi Pharmaceutical’s Rosuzet has been the number one prescribed drug in the outpatient pharmacy market in South Korea for two consecutive years.
Frequently Asked Questions (FAQ)
Q: What are the benefits of low-dose combination therapies?
A: They can offer improved efficacy, reduced side effects, and better patient adherence compared to traditional step-wise treatment approaches.
Q: What is Amoprel used for?
A: Amoprel is a triple combination antihypertensive medication used to treat high blood pressure.
Q: What is Rosuzet used for?
A: Rosuzet is a combination medication used to treat high cholesterol (hyperlipidemia).
Q: Where can I find more information about these medications?
A: Consult with your healthcare provider or visit the Hanmi Pharmaceutical website for more details.
Pro Tip: Discuss with your doctor whether a low-dose combination therapy might be a suitable option for managing your blood pressure or cholesterol levels.
We encourage you to explore other articles on our website to learn more about cardiovascular health and treatment options. Share your thoughts and experiences in the comments below!
